대사이상 관련 지방간질환의 생간건비탕 치험 1례
Case Report of Metabolic Dysfunction-Associated Fatty Liver Disease Treated with Saenggangunbi-tang
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: This study identified the effects of Korean medicine treatment on a patient with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A 43-year-old man with MAFLD was treated with Saenggangunbi-tang with regular exercise from August 13, 2022, to December 24, 2022, to reduce fatigue and dyspepsia and to improve laboratory findings, such as liver enzymes and lipid profiles. We observed changes in symptoms and laboratory findings during the approximately four-month treatment. Results: Treatment with Saenggangunbi-tang resulted in decreased serum levels of liver enzymes, triglycerides, hepatic steatosis index scores, and clinical symptoms. During the treatment, the patient performed regular exercise; however, there was no significant change in body weight until the end of the study. Conclusion: This study suggests the availability of Saenggangunbi-tang as a therapeutic option for managing MAFLD patients.
Abstract
Objective: This study identified the effects of Korean medicine treatment on a patient with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A 43-year-old man with MAFLD was treated with Saenggangunbi-tang with regular exercise from August 13, 2022, to December 24, 2022, to reduce fatigue and dyspepsia and to improve laboratory findings, such as liver enzymes and lipid profiles. We observed changes in symptoms and laboratory findings during the approximately four-month treatment. Results: Treatment with Saenggangunbi-tang resulted in decreased serum levels of liver enzymes, triglycerides, hepatic steatosis index scores, and clinical symptoms. During the treatment, the patient performed regular exercise; however, there was no significant change in body weight until the end of the study. Conclusion: This study suggests the availability of Saenggangunbi-tang as a therapeutic option for managing MAFLD patients.
참고문헌 (20)
- Rui F, "Renaming NAFLD to MAFLD : Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management", Infectious Microbes & Diseases, 4(2), pp.49~55 (2022)
- Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus state", J Hepatol, 73(1), pp.202~209 (2020)
- Stefan N, "Non-alcoholic fatty liver disease : causes, diagnosis, cardiometabolic consequences, and treatment strategies", Lancet, 7(4), pp.313~324 (2019)
- Yin X, "Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease", Int J Mol Sci, 24(3), pp.1~23 (2023)
- Rojas Á, "Emerging pharmacological treatment options of MAFLD", Ther Adv Endocrinol Metab, 13, pp.1~15 (2022)
- 이유리, "비알콜성 지방간질환의 한방치료에 대한 체계적 문헌고찰", 대한한방내과학회지, 40(1), pp.13~37 (2019), 대한한방내과학회[DOI]
- Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42(7), pp.503~508 (2010)
- 김문영, "비알코올 지방간 질환의 진단", 대한내과학회지, 86(4), pp.405~415 (2014), 대한내과학회[DOI]
- Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19(10), 2172~2181
- Eslam M, "MAFLD : A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease", Gastroenterol, 150(7), pp.1999~2014 (2020)
- Strauss S, "Interobserver and intraobserver variability in the sonographic assessment of fatty liver", Am J Roentgenol, 189(6), pp.320~323 (2007)
- Nakatsuka T, "Changing clinical management of NAFLD in Asia", Liver Int, 42(9), pp.1955~1968 (2022)
- van der Poorten D, "Visceral fat : a key mediator of steatohepatitis in metabolic liver disease", Hepatology, 48(2), pp.449~457 (2008)
- Woo HJ, "Oriental Internal Medicine on Hepatobiliary System, Hematology and Toxicology", pp.307~315 (2016), Nado
- 김어진, "비만과 이상지질혈증을 동반한 비알코올 지방간질환 환자 치험 1례", 대한한방내과학회지, 43(2), pp.184~190 (2022), 대한한방내과학회[DOI]
- 김하연, "대사증후군을 동반한 비알코올성 지방간염 치험 1례", 대한한방내과학회지, 38(2), pp.125~130 (2017), 대한한방내과학회
- Tomizawa M, "Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes", Biomed Rep, 2(5), pp.633~636 (2014)
- Nengguang F, "Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease : a cross-sectional study", Lipids Health Dis, 18(39), pp.1~6 (2019)
- Park SH, "Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men", J Gastroenterol Hepatol, 19(6), pp.694~698 (2004)
- 정연우, "Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B", Journal of Korean Medical Science, 35(17), pp.1~11 (2020), 대한의학회[DOI]